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ABSTRACT
Marijuana is one of the most commonly used illicit substances in the U.S. and its rapid
implementation as a form of treatment has sparked significant national attention and
debate among clinicians. In the United States, medical marijuana (MM) may be
recommended as a form of treatment by certified physicians. The purpose of this study
was to examine licensed physicians’ support for recommending MM for various health
conditions, their perceived knowledge regarding its efficacy as treatment, and their
attitudes toward MM. This study employed a correlational design utilizing a selfadministered, online survey (PCOM REDCap) to collect quantitative information from
licensed and actively practicing physicians in the U.S. (N=24). The survey link generated
by REDCap was posted to the private PCOM group page and permission was obtained to
post on other physician-focused Facebook pages and listservs. The study also recruited
physician-level using ResearchMatch.org. Two 5-point Likert-type scales had been
developed to measure the degree to which participants would support recommending
MM to treat numerous health conditions and to identify the perceived strength of
empirical support for its treatment of each condition. Participants completed a 1 item 5point Likert-type Provider Attitudes and Beliefs Regarding Cannabis scale. It was
hypothesized that physicians’ support for recommending MM would be significantly and
positively correlated with their perceptions of the strength of its empirical evidence and
that physicians’ support for recommending MM would be significantly and positively
correlated with their attitudes towards MM. Descriptive statistics were used to
characterize the sample and examine specific attitudes and perceptions regarding its use.
Findings from this study may offer additional insight on physicians’ varying attitudes and
support for MM.
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CHAPTER 1: INTRODUCTION
Statement of the Problem
Cannabis is the most commonly abused illicit substance worldwide, with an
estimated 147 million users (approximately 2.5% of the entire world population).
The United States is the number-one consumer of cannabis in the world (22.2 million
Americans aged 12 years and older reported use), and it is the third most commonly used
substance in the United States after alcohol and nicotine (National Association of Social
Workers, 2017; National Institute of Drug Abuse, 2017; World Health Organization,
2016). Over recent years, cannabis use and its medical efficacy have garnered increasing
national support across the United States, with 36 states now approving it for medical
purposes, 32 states decriminalizing it, and 17 states fully legalizing its use (Map of
Marijuana Legality by State, 2021). Information pulled from ballot measures, as well
as from public opinion polls, has revealed that approximately 60% of Americans support
recreational use of cannabis, and 81% support its implementation as a form of medicine
even though the federal government still recognizes it as a Schedule I substance (i.e.,
high propensity for abuse, no medical benefits; Bridgeman & Abazia, 2017; Quinnipiac
University, 2016; & Swift, 2016). Some other substances that fit the criteria of a
Schedule I category are MDMA (ecstasy), LSD, and heroin (Nutt et al., 2013).
In the United States, medical marijuana (MM) may be recommended by certified
physicians as a form of treatment for at least 23 health conditions, yet literature is limited
regarding physicians’ attitudes regarding its use or knowledge about its efficacy (Restore
Integrative Wellness Center, 2018; Rubin, 2017). Cannabis’s rapid implementation as a
form of treatment has sparked significant national attention and debate among clinicians,
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and data are limited regarding physicians’ conceptualizations of cannabis as a form of
effective medication (National Institute of Drug Abuse, 2017; Rubin, 2017).
Definition and Purpose of the Study
MM is defined as marijuana that may be recommended by certified physicians as
a form of treatment (Restore Integrative Wellness Center, 2018; Rubin, 2017). The
purpose of this study was to develop more insight regarding how physicians in the United
States have come to conceptualize cannabis as a form of medicine to treat numerous
health conditions. Specifically, this study examined the level of support physicians have
for the use of MM as a form of treatment and identified whether perceptions of empirical
support for MM influenced their attitudes and beliefs toward MM. As marijuana is one of
the most commonly misused illicit substances in the United States, physicians’ current
conceptualizations regarding cannabis for medical purposes are important to understand.
Research Question and Hypotheses
The research question for this study was as follows: How are physicians’
perceptions of existing evidence, attitudes, and levels of support for MM associated with
one another?
Hypothesis 1
H1: Physicians’ level of support for MM will be significantly and positively
associated with their perceptions of the strength of its empirical evidence.
Rationale for H : Prior research has provided some indication that physicians are
1

more likely to recommend MM for specific health conditions they believe to be
supported by empirical evidence (Jacobs et al., 2019; Kondrad & Reid, 2013). In
addition, other research has indicated that many clinicians may have adopted a more
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apprehensive attitude toward MM as a result of limited education and training in this area
(Rubin, 2017).
Hypothesis 2
H2: Physicians’ level of support for MM will be significantly and positively
associated with their attitudes toward marijuana (medical or not).
Rationale for H : Previous research has found that physicians who had
2

recommended MM in the past possessed more favorable attitudes on its efficacy as a
form of treatment and were less critical of its risks than physicians who had not
recommended cannabis (Kondrad & Reid, 2013). Observing the attitudes of U.S,
physicians regarding MM and how closely they correlate to their belief that it is a
substance that should be recommended for certain conditions would be interesting.
Hypothesis 3
H3: Physicians’ perceptions of evidence will be significantly and positively
correlated with their attitudes toward MM.
Rationale for H3: Physicians have shown in prior research that their preference to
either recommend or not recommend MM was most strongly influenced by
literature/empirical evidence when compared to other media, such as news media,
personal experiences with patients, and other physicians’ views. (Kondrad & Reid, 2013).
This helps reinforce the idea that physicians’ conceptualizations and attitudes toward
MM may be strongly influenced by research as well. Physicians have shown in previous
research that their preference to either recommend or not recommend MM was most
strongly influenced by literature/empirical evidence when compared to other media (e.g.,
news, experiences with patients, other physicians; Kondrad & Reid, 2013). This helps
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strongly influenced by research as well.

5
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CHAPTER 2: LITERATURE REVIEW
Brief History of Marijuana
Medical marijuana (MM) has an extensive history of use by a range of different
cultures. Some experts believe that marijuana was initially used as herbal medication in
central Asia more than 10,000 years ago, spread throughout Europe, transitioned into use
by African natives, and eventually was introduced into the United States through
colonization (Pisanti & Bifulco, 2019). Early American colonists incorporated the use
of cannabis (hemp) for grain such as clothing, paper, sails, rope, and consumption which
dated back to the Neolithic Age in Japan and China (Barber, 1992; Stafford & Bigwood,
1992). Early legislative reforms in America dating back to the 1600s were more
supportive of cannabis because of these numerous advantages in addition to it being
produced quickly and easily cultivated compared to other plants (Johnson, 2017).
However, between 1906-1938, the United States began reinforcing laws prohibiting
the use of cannabis, which was categorized as a poison in many states during this time
period. The United States began promoting misleading and inaccurate effects of
marijuana throughout the 1930s, and this led to more strict legal repercussions throughout
the 1950s. During this time period, marijuana use was associated with negative social
connotations and violent behaviors within various minority groups (i.e., Mexican,
African, and Japanese American; Warf, 2014).
MM has become increasingly more accessible for medical purposes throughout
the United States ever since the Compassionate Use Act was passed in California in 1996
(Rojas, 1998). Over the past few years, more states have experienced policy reforms that
approved MM for medical purposes, decimalized MM, or completely legalized MM for
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recreational use by adults. Such reforms have helped MM to receive approval for
recommendation by physicians for certain health conditions in 36 of 50 states (Map of
Marijuana Legality by State, 2021). However, according to the U.S. Drug Enforcement
Agency’s (DEA) Comprehensive Drug Abuse Prevention and Control Act of 1970,
cannabis is currently regarded as a Schedule I controlled substance by the federal
government. This places cannabis in the same category as heroin and cocaine and
identifies it as a substance that is addictive with no clinical benefits (Bridgeman &
Abazia, 2017; Quinnipiac University, 2016; Swift, 2016).
Why Marijuana Is Used
Patrick et al. (2011) found that individuals between 18-30 years old continued to
use marijuana because it helped them relax and/or get high. Other research had found that
frequency of smoking cannabis decreased with age. Previous research had found that
among veterans, those who used cannabis for medical purposes were much more likely to
meet the criteria for PTSD and had much more incentive to smoke cannabis in order to
help them manage health-related conditions, such as stress/anxiety, pain, depression, and
insomnia, as compared to veterans who smoked recreationally (Metrik et al., 2018).
Additional research has found some patients who used marijuana for medical purposes
perceived it as providing relief for a number of different symptoms associated with sleep,
pain, and anxiety, although routes of administration did differ (Walsh et al., 2013).
Scope of Cannabis Use/Addiction
Cannabis is the most commonly abused illicit substance worldwide and the third
most commonly used drug in the United States after alcohol and nicotine (National
Institute of Drug Abuse, 2017; World Health Organization, 2016). Budney et al. (2019)
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and the National Association of Social Workers (2017) reported that as many as 7% of
Americans have identified themselves as habitual cannabis users and that more than one
third have admitted to using it in the past. Additionally, according to epidemiological
data, a range of anywhere between 10% 30% of users report symptoms consistent with
cannabis use disorder (Budney et al., 2019). Approximately 147 million individuals
consume cannabis annually, making up approximately 2.5% of the entire population
of the world (World Health Organization, 2016). Prevalent use of cannabis has also
transitioned into common use among American adolescents, 22.2 million of whom were
12 years old or older and reported regular consumption (Bridgeman & Abazia, 2017;
Office of National Drug Control Policy, 2016; Substance Abuse and Mental Health
Services Administration, 2016). In 2012, nearly 2 million people (or nearly 5% of the
population) in California reported use of cannabis for medical reasons, but this did not
take into account individuals who decided to use this substance recreationally (Haberstick
et al., 2014). This led to increased concerns not only regarding the legal and ethical
ramifications associated with its distribution, but also in regard to the degree to which
this substance is efficacious in treating some health conditions (Bridgeman & Abazia,
2017).
Race, Gender, and Age
Additional research has found that young adults aged 20-24 years old are the
most prevalent users of cannabis globally (Degenhardt et al. 2013; Russell et al., 2018).
Carliner et al., (2017) had found that between 2002-2014, increased cannabis use was
greater for men then for women. This gender gap in cannabis use was at its highest level
among low-income men during the Great Recession from 2007-2014. Furthermore, other
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research has suggested that African American individuals tend to use marijuana more
frequently than individuals of otherraces/ethnicities (Pacek et al., 2012).
Routes of Administration
Cannabis is most commonly smoked, but vaporizers, dabbing, and edibles remain
popular forms of use as well. Other routes of administration include patches, pills,
tinctures, transdermal topicals (e.g., cannabis-infused lotions, balms, oils), intravenous
routes (e.g., via syringe), and rectal routes (e.g., suppositories; Geshtakovska & Stefkov,
2016; Shiplo et al., 2016).
Smoking
Smoking cannabis (e.g., joint, blunt, spliff, water-pipe/bong) remains the most
common route of administration among Americans. Previous and current cannabis users
possessed a preference to smoking over other routes of administration, according to
a national survey taken in 2014 (Schauer et al., 2016). Studies have shown that among
middle- and high-school students and Baby Boomers, smoking was also the most
common route of administration (Johnson et al., 2016; Murphy et al., 2015). When
cannabis is smoked, THC and other chemicals enter the bloodstream through the lungs
(Brady & Li, 2014). Typically, this can onset a brisk physiological response as some of
these chemicals from the plant cross the blood-brain barrier. Users frequently report
experiencing increased relaxation and other euphoric sensations that may include
increased sensitivity to sensory stimuli (e.g., colors being more poignant or bright), shift
in mood, altered sense of time perception, and/or increase in appetite. These processes
may lessen when cannabis is consumed with food or beverages as a result of the digestive
process. Cannabis may also be ingested orally as an attempt to achieve similar effects to
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smoking, but this approach typically includes a delayed effect and may increase chances
of overdose, as more THC may be introduced than the user may have initially intended.
THC is the primary psychoactive ingredient in marijuana and achieves this effect on the
brain by binding to one’s CB1 receptors (Secci et al., 2019).
Some research has shown that increased exposure to THC increases glutamate
levels in rats and has led some physicians to believe that THC binding with CB1
receptors helps release glutamate (Navarrete & Araque, 2008; Pistis et al., 2002). Some
researchers also suspect that this process is possible because THC affects astrocytes, cells
in the brain and spinal cord that assist with the functionality of the CB1 receptors,
although the specifics as to how remain a topic of debate (Secci et al., 2019).
Additionally, inconsistent findings between animal and human research have generated
ambiguity regarding the significance of this process in terms of how THC affects and
influences specific brain regions (Secci et al., 2019).
Overdosing on cannabis is possible if ingesting a product that is potent enough
and may cause some individuals to experience more aversive effects, such as a sudden
increase in anxiety, panic, and fear of either others and/or the environment they are
in (Buckner et al., 2014; Hall & Solowij, 1998; Ramaekers et al., 2006). In other
instances, individuals who ingested large amounts of cannabis experienced more severe
side effects, including hallucinations, delusions, and acute psychosis, although such
reactions were temporary (Hall & Degenhardt, 2009). Otherresearch identified
respiratory symptoms, such as coughing and wheezing; constriction of the airways in the
lungs; and history of being linked with chronic bronchitis (Russell et al., 2018; Gates et
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al., 2014). Individuals who managed to reduce their smoking or to quit have also
demonstrated a decrease in respiratory dysfunction (Hancox et al., 2015).
Smoking cannabis has also been shown to be concurrent with smoking tobacco,
and concurrent use of marijuana and tobacco has also been associated with worse health
outcomes than those of individuals who smoked only cannabis. Some of these worse
health outcomes included respiratory dysfunction, increased risk for cannabis use
disorder, and increase in mental health symptoms (Agrawal et al., 2012; Ramo et al.,
2012). Furthermore, individuals who smoke blunts (i.e., cannabis rolled into tobacco leaf
paper) have been associated with an increased risk for cannabis use disorder and nicotine
dependence compared to individuals who smoked marijuana but not blunts or who did
not smoke (Fairman, 2015; Timberlake, 2009).
Vaporizers
One form of cannabis administration that has been increasing in popularity is
vaporizers(e.g., vape pens, electronic cigarettes, vape mods). Through this method of
use, cannabis is heated electronically and inhaled in the form of vapor. The availability
of vape pens and similar devices has increased substantially, and they continue to grow in
popularity in the United States (Russell et al., 2018). For instance, in a large online
survey conducted in 2016 (n = 2,910) 61% of Americans identified themselves as lifetime users of cannabis vaporizers, and 37% reported current use in the past month. Vape
pens (45%) were the most popular form of vaporizing cannabis, ahead of other forms of
vaping, such as tabletops, portables, and e-cigarettes (Lee et al., 2016). In one study,
participants reported that their top reasons for preferring vaporizers over other forms
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of cannabis consumption was its convenience and discretion, permitting them to use
in public locations (Jones et al., 2016).
One study found that vaporizers absorbed THC from cannabis more effectively
than simply smoking cannabis. The vaporizer also did not significantly increase carbon
monoxide (CO) levels if at all compared to smoking cannabis, which did increase
CO levels. This indicates that participants who vaped were not exposed to “gaseous
combustion toxins,” which are harmful. Participants also reported that they preferred
vaping over smoking, suggesting that vaping is safer and “cleaner” than smoking
marijuana as a result of how the THC is processed (Abrams et al., 2007). Additionally,
some previous research has shown that participants who switched from smoking cannabis
to vaping for 1 month yielded significant improvements in respiratory functioning
(Earleywine & Van Dam, 2010; Van Dam & Earleywine, 2010). Additionally, in a large
self-report survey (n = 6,883) participants who reported using vaporizers were
significantly less likely to report respiratory issues than those who did not use vaporizers
(Earleywine & Barnwell, 2007). Additionally, some research has shown that vaporizer
use helped participants decrease or quit smoking cannabis, although the specific reasons
as to why remain unclear (Etter, 2015; Gartner, 2015).
Edibles and Drinkables
Cannabis products may also be presented in the form of edibles (e.g., cannabisinfused brownies, drinks, candies), one of the more popular forms of consumption
among Americans. In 2014 alone, Colorado produced $700 million in medical and
recreational sales of marijuana, of which edibles accounted for approximately 40%
(Weiss, 2015). Some research has indicated that edibles tend to be more popular in states
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where marijuana is legalized as compared to those in which it is not, are used more by
women than men, and have a high rate of use among current cannabis users in
Washington (of 1,687 current marijuana-using surveys, 78% reported edible consumption
in the previous year; Borodovsky et al., 2016; Friese et al., 2016; Kilmer et al., 2013).
Typically, after ingesting cannabis in an edible form, the psychoactive effects tend to
be delayed, but may be unpredictable and excessive. Some products may possess more
than 4 times the level of THC than is safe, possibly leading to severe anxiety attacks and
serious psychoactive symptoms (MacCoun & Mello, 2015). Other reported side effects
include drowsiness/lethargy, tachycardia, agitation/irritability, and confusion (Cao et al.,
2016).
Cannabis edibles have grown quickly in popularity in such states as Colorado and
Washington since recreational use has been legalized. This has also led to a steady
increase in cannabis-related emergency room visits and U.S. poison control calls and
has prompted four states (i.e., Alaska, Colorado, Oregon, and Washington) to require
specified labels regarding dosage in order to try to decrease such occurrences (Gourdet et
al., 2017).
Dabs
Dabs, or butane hash oil (BHO), is a wax-like substance created by extracting
THC from a cannabis plant. It can reach THC concentrations levels of 70%-90%,
whereas plant-based concentrations range between 3%-6%. As a result, dabs can lead to
psychotic episodes and increase risk of injury (Keller et al., 2016). Typically, dabs are
placed onto a piece of glass and heated with a blowtorch until they are vaporized and the
individual can inhale the vapors in order to feel the psychoactive effects (Loflin &
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Earleywine, 2014). Over the last few years, emergency admissions related to BHOextraction injuries and burns have increased (Bell et al., 2015; Jensen et al., 2015).
Additionally, regular dabbing increases the risk of developing cannabis use disorder as a
result of increased tolerance and consistent increase in dosage (Loflin & Earleywine,
2014).
Other Routes of Administration
Other routes of administration include patches, pills, tinctures, oils, transdermal
tropical, suppositories, and intravenous routes (i.e., syringes and rectal routes).
Unfortunately, prevalence and outcome data regarding these routes of administration are
limited within the academic literature. This is also the result of the rare use of these
routes of administration among the general population (Russell et al., 2018).
Cannabinoid Receptors and Mechanism of Action
The two major primary components of marijuana are phytocannabinoids: THC
and cannabidiol (CBD), both of which are cannabinoids. Cannabinoid refers to the active
components produced by the different strains of marijuana, such as sativa and indica. Of
these two primary components, THC is recognized as one of the primary cannabinoids
responsible for generating the psychoactive effects of cannabis and is identified as the
primary ingredient that helps to induce psychosis, cognitive delay, and panic attacks if
misused. Some previous research has highlighted the fact that the concentration of THC
has substantially increased over the past 24 years, increasing as much as anywhere
between 15%-20% in some areas. Cannabis affects the endocannabinoid system (ECS),
which is composed of cannabinoid receptors in the brain and within the immune system.
The two primary receptors within the ECS are cannabinoid receptor type-1 (CB1) and
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cannabinoid receptor type-2 (CB2). The CB1 and CB2 receptors have a greater
concentration in the neocortex, basil ganglia, and hippocampus and possess a great
influence over memories, appetite, and responses to stress function. Additionally, the
ways one processes rewards and reinforcement are also influenced by the CB1 and CB2
receptors (Rong et al., 2017).
CBD is a naturally occurring cannabinoid in cannabis that acts as an antagonist
at the CB1 receptor site and as an inverse agonist at CB2 receptors. It also prevents or
slows down the degradation of anadamide (AEA), a naturally occurring
neurotransmitter responsible for a wide array of functions, such as memory, motivation,
and appetite, and has been shown to help with neural pruning and synaptic restructuring.
In contrast, THC depletes AEA, and the rate at which AEA is diminished may mediate
some of the psychoactive effects of THC (Rong et al., 2017; Wilkie et al., 2016). AEA is
also responsible for the development of new nerve cells and can serve as a natural
antianxiety agent and antidepressant. It does, however, break down quickly, but like
marijuana, it binds effectively with the CB1 and CB2 receptors. When cannabis is
ingested, it contains THC, a cannabinoid that resembles AEA, and is able to bind to the
CB1 receptor. This binding process of cannabinoids to the receptors (especially CB1),
triggers the psychoactive properties of the substances (Rodriguez de Fonseca, et al.,
2004; Rong et al., 2017; Wilkie et al., 2016).
Legalization
Medical cannabis has become increasingly more accessible for medical
purposes throughout the United States ever since the Compassionate Use Act was passed
in California in 1996 (Carr & Schatman, 2019). During the past few years, more states
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have enacted policy reforms that have approved MM for medical purposes, were
decimalized, or were completely legalized for recreational use by adults. Currently, 36
states have approved the use of medical cannabis, 32 states have decriminalized it, and 17
states have fully legalized its use (Map of Marijuana Legality by State, 2021). However,
according to the U.S. DEA’s Comprehensive Drug Abuse Prevention and Control Act of
1970, marijuana is currently regarded as a Schedule I controlled substance. Schedule I
substances are considered to possess a high risk for abuse and lack any medical use.
Some alternative examples of Schedule I drugs include heroin, cocaine, and narcotics
(Koocher & Shortt, 2018). Some advocates for legalized cannabis use have expressed
concern over the association of cannabis within a category of other substances that
possess a much higher risk for more severe and detrimental health consequences
(Fergusson et al., 2006; Levitan, 2015).
Furthermore, legislatively the federal government cannot impose its laws on
cannabis in states where it has become legalized because Congress has passed such acts
as the Consolidated Appropriations Act of 2018, which helps prevent the federal
government from using its budget funds to override marijuana laws. However, there are
some exceptions, mainly if the state and federal laws happen to conflict. In such a case,
the federal law overrides the authority of the state, as is stated in the Supremacy Clause in
the United States Constitution (Koocher & Shortt, 2018).
Medicalization, State of Research, Number of Ailments Found To Be
Effective/Limitations
Some previous research has found that MM can be used as a form of efficacious
treatment for certain conditions, including chronic pain, multiple sclerosis, nausea, side
effects of chemotherapy, lack of appetite, and sleep disorders (Abrams, 2018; Belendiuk
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et al., 2015). In regard to relief of side effects of chemotherapy, a study was conducted by
Parker, et al. (2006) in which house musk shrews were exposed to contextual cues that
were paired with lithium chloride (LiCl) injections and had been conditioned to vomit
even when LiCl was not administered. The investigators found that exposure of CB1 and
CB2 receptors to cannabinoids helped suppress the vomit response as opposed to
pretreatment that included ondansetron. In a study that included 600 patients, Ben
Amar (2006) reviewed the outcomes of 15 randomized clinical trials in which nabilone, a
synthetic cannabinoid, was compared to either a placebo or other antiemetic medications.
The results indicated that nabilone was much more effective as a form of treatment than
prochlorperazine, domperidone, and alizapride, and patients expressed a stronger
preference for nabilone when asked which medication they would like to use. However,
variability and inconsistencies across the 15 clinical trials limited the generalizability of
the results of this study.
Previous research also explored the use of MM to treat cancer-related neuropathic pain
(Manzanares et al., 2006). Studies conducted by Fine and Rosenfeld (2013) found that
cannabinoids had a similar concentration and distribution in the brain to those of opioid
receptors, while research by Ibrahim et al. (2005) found indications that cannabinoids
may possess anti-inflammatory characteristics by interacting with mast cell receptors.
Additionally, published clinical trials have shown patients diagnosed with cancer
recognized THC as a superior analgesic to placebo when administered at 15-20 mg and as
more analgesic and sedating than codeine when administered at 10 mg. Some of
the limitations of these trials include small sample sizes and dated information from more
than 40 years ago (Noyes, Brunk, Baram, & Canter, 1975; Noyes et al., 1975).
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More recent clinical trials included 360 randomized patients suffering from cancer
and opioid-refractory pain who were administered nabiximol, a cannabis extract
composed of THC and CBD. Nabiximol was administered at low, medium, and high
doses and then compared to placebo. The trial found that at low and medium doses,
patients recognized nabiximol’s analgesic effects more than those of the placebo, but
higher doses did not differ from the lower- and medium-dose results (Portenoy et al.,
2012). In a trial conducted by Johnson et al. (2010), 177 patients suffering from cancer
pain despite opioid use were exposed to a THC and CBD treatment, a THC only
treatment, and a placebo. Participants in the combined CBD and THC group reported
significant decrease in pain symptoms whereas the THC only treatment did not differ
from the placebo. However, some of the limitations of such studies are reliance on selfreport measures and/or small effect sizes. Additionally, no studies currently present
cannabis or cannabinoids as first-line agents (Whiting et al., 2015; Wilkinson & D’Souza,
2014).
Furthermore, for some conditions such as PTSD, Crohn’s disease, AIDS/HIV,
and/or Alzheimer’s disease, tests of the efficacy of marijuana use through clinically
controlled, randomized trials is severely lacking in the literature. Instead, much of the
research concerning such medical conditions and the medical impact cannabis has on
them is testimonial. Additionally, the amount of marijuana that must be administered in
order for it to achieve a medically efficacious effect is not specified, nor do some of the
articles specify the mode of administration used to treat a specific symptom and/or
condition. This makes finding an appropriate dose challenging, and clinicians must be
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wary of other factors, such as tolerance, dependence, and withdrawal symptoms/effects if
the patient chooses to discontinue.
Cannabis also contains more than 100 cannabinoids, terpenoids, and flavonoids,
all of which may have different effects on different individuals. THC is the primary
psychoactive ingredient, but others may be able to avert some of the negative side effects
of THC. One should note that although a cannabis pill approved by the FDA does exist,
most users seem to prefer to smoke as a way to control for euphoric sensations that may
be more difficult to achieve through pill administration (Wilkinson & D’Souza 2014).
Additional research has found that marijuana use may increase the risk for some
individuals for developing acute psychosis, and it found that a structural shift in the brain
of long-time users contributes to lower IQ over time (Wilkinson & D’Souza 2014).
Furthermore, a recent meta-analysis was conducted to examine the
specific conditions for which MM was effective (Whiting et al., 2015). The review found
MM to be effective for treating tic severity caused by Tourette syndrome, decreasing
symptoms of chronic pain, and improving quality of sleep. Also, researchers found
that cannabis may relieve symptoms of anxiety, but none of these studies featured
individuals who suffered only from anxiety. MM was not found to be effective for
treating symptoms of nausea and vomiting resulting from chemotherapy, increasing
appetite stimulation in patients suffering from HIV/AIDS, improving symptoms of
spasticity caused by multiple sclerosis or paraplegia, or improving symptoms of
psychosis and glaucoma. Furthermore, no study examining the effects of MM met
inclusion criteria for the treatment of depression. Additionally, a body of literature
explores cannabis as a potential antitumor substance.
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Older research, such as that conducted by Munson et al., 1975) found that THC
administration decreased tumor growth in mice. More recent research (Bowles et al.,
2012; Pisanti et al., 2009; Abrams & Guzman, 2015) found that cannabinoids may be
used to decrease the rate at which tumors grow by decreasing cellular proliferation and
increasing apoptosis within cancer cells. Other research found that when synthetic
cannabinoids bind with the CB2 receptors, cell proliferation of cancer cells decreases and
cancer metastasis may potentially decrease. This study was replicated with mice, and
similar results were achieved (Qamri et al., 2009).
Attitudes/Acceptance Among Physicians and Doctoral/Medical Students
Despite the growing popularity and approval of cannabis use among Americans
(recent polls have identified that 60% of Americans approved of recreational use of
marijuana, and 80% supported MM), some physicians have reported mixed views in
regard to whether they would feel comfortable prescribing cannabis for any medical
reason (Mental Health Weekly, 2013). Other bodies of literature have touched upon the
idea of the number of physicians who either felt as though they did not have enough
research to guide their support for MM use or reported not undergoing enough
educational training in regard to the potential benefits and/or drawbacks of its use,
especially over an extended period of time (Rubin, 2017). Many physicians do not agree
with medicalization of marijuana. Researchers (Charuvastra et al., 2005) found that of
960 surveyed physicians, 36% believed prescribed cannabis should be legalized, and 26%
were neutral to the notion. The study also found that obstetricians-gynecologists and
internal medicine physicians expressed that they were significantly more likely to support
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its prescription as compared to physicians in other fields (e.g., family
physicians, internists, psychiatrists, addiction specialists).
A study composed of 209 hospice health professionals found that the vast
majority (90%) of the participants believed that cannabis should be legalized,
reported ignoring patients’ cannabis usage if it alleviated their symptoms (75%), and
were supportive of family members obtaining small amounts for loved ones to use (70%),
or of obtaining it from a pharmacy (88%). Non-physicians (i.e., nurses and social
workers) generally agreed that cannabis possessed health benefits whereas physicians
“somewhat agreed” to this notion. Respondents were divided regarding the branch of
government that should be responsible for legalizing cannabis, and respondents older
than 50 years were more likely to disagree with the idea that cannabis is addictive
compared to younger participants (Uritsky et al., 2011). Furthermore, nearly half
(47.8%) the sample reported being asked about cannabis use by either their patients or
their family members.
Research conducted by Ziemianski et al. 2015) surveyed 426 physicians regarding
theirknowledge, experiences, attitudes, and barriers about MM. Physicians identified
lowest level of knowledge regarding cannabis usage, dosing, and discrepancy between
cannabinoid medications and other cannabis products. The vast majority of participants
expressed a desire for further, more in depth education regarding these topics. A majority
of Canadian physicians (79%) reported being approached by patients and/or family
members regarding MM usage whereas 39% reported initiating the discussion
themselves. About two thirds of the sample (65%) reported that one of the greatest
barriers was concern about whether clients who requested MM under the pretense of
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treatment would in reality be using it for recreational purposes. Canadian physicians also
expressed possessing additional data regarding risks and benefits of cannabis use.
In regard to their attitudes, a majority believed that either specialized physicians
(85%) or family physicians (74%) should be able to authorize cannabis usage for their
patients, but they were divided when asked about whether nurses should have this same
authority. Twenty-five percent of respondents believed that nurses should, but 60% did
not agree. A majority did agree that other healthcare professionals should not be able to
authorize cannabis use for patients, and 70% believed that with additional education they
would be able to make better decisions regarding whether a client needed MM.
In another research study, 236 medical students participated in a survey about
their attitudes toward cannabis. Approximately two thirds of the sample (64%) reported
support for cannabis legalization, yet 77% and 68% reported a belief that marijuana had
the potential to be harmful psychologically and physically, respectively. A minority of
the sample (29%) stated they would recommend cannabis under current law, and this
percentage increased to 45% if marijuana were legally available. Additionally, the vast
majority of the sample (97%) believed more research should be conducted and that
cannabis could play a role in treatment (Chan et al. 2017).
Research conducted by Kondrad and Reid (2013) found that the three most
common conditions for which MM is recommended by family physicians is pain,
nausea, and cancer. The research also showcased how family physicians relied most
heavily on medical literature and personal experiences with a client as their primary
sources of information regarding MM efficacy. Personal experiences with a client and
medical literature were also the two most relied upon factors as to whether a physician
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would decide to recommend or not recommend MM. Of the 520 family physicians who
participated in the study, 46% did not support family physicians recommending MM as
opposed to 19% who did. Most family physicians in this study were not convinced of
MM’s health benefits, but a majority (92%) believed future research should be
conducted, and 81% believed recommenders should be trained.
Alternatively, in a poll conducted by Adler and Colbert (2013), of 1,446
physicians, 76% reported they would approve the use of cannabis for medical reasons.
Respondents cited their support for MM out of a belief that they were responsible for
helping to alleviate the suffering of their clients (Adler & Colbert, 2013). Some literature
explores the varying degrees of support of MM from physicians in different specialties.
One such study was conducted by Ebert et al. (2015) in which Israeli oncologists, pain
specialists, psychiatrists, neurologists, and rehabilitation physicians all agreed that MM
could be helpful for terminally ill patients, that additional education is required for
physicians, that certified recommenders should be trained, that MM may have potential
for therapeutic purposes, and that MM can be incorporated as a legitimate form of
treatment and therapy. Pain physicians and oncologists disagreed with the other
specialized physicians that MM could undermine mental health, but the majority (73%)
agreed that patients should not obtain cannabis from growers and that some clients desire
MM for recreational reasons (69%). Physicians were divided regarding cannabis
legalization for recreational purposes. Of those surveyed, 54% objected, 22% supported
cannabis legalization for recreational purposes, and 15% were neutral. Compared to some
other research, there was some partial acceptance of MM among this sample of
physicians.
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In a study conducted by Ablin et al. (2016), a sample of 23 Israeli rheumatologists
surveyed their attitudes regarding MM. Three quarters of the sample lacked knowledge
regarding cannabinoid molecules and lacked the confidence to prescribe MM. Despite
this lack of knowledge, a majority of participants expressed a belief that MM could be
implemented in the future to treat rheumatic disease. Additionally, 82% of the sample
reported a consideration to prescribe MM if conventional medication failed to treat a
client’s symptoms. The responders also identified concerns about recreational usage of
prescribed MM, previous history of addiction with a client asking for a prescription, the
potential for motor vehicle accidents, and interaction between cannabis and other
medications.
Another study explored oncologists’ attitudes toward MM. The study was
composed of 237 participants, of whom only 30% felt confident and well informed
enough to provide a MM recommendation. Although 80% of oncologists reported
discussing MM with patients and their families, only 46% had ever provided a
recommendation for it. Additionally, 65% of responders also reported the belief that they
felt that MM was more effective in treating anorexia and cachexia compared to
standard medication. Furthermore, oncologists practicing in the South (68%) were less
likely to discuss MM as an option compared to oncologists practicing in the West
(94%). Oncologists in the West (84%) were also more likely to recommend MM
compared to oncologists in the South (34%) as well. Oncologists were also divided on
whether MM was an effective analgesic. Only 34% viewed MM as more effective
than standard medication, 32% believed it was less effective, and 33% stated they did not
know. Of the oncologists surveyed, 64% believed MM was equally or more effective
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than standard medication for treating cachexia, 48% for cancer, 45% for anxiety, 40% for
general coping, and 35% for poor sleep. Most oncologists in the study did not view MM
as more dangerous than opioids in terms of overdose death but did perceive it to place
users at slightly higher risk for developing paranoia and confusion (Braun et al. 2018).
One should be aware of not only the number of physicians who may be in favor of
or opposed to MM, but also the factors that may influence these decisions or perceptions.
According to cognitive-behavioral theory, one’s perceptions of the empirical evidence for
or against a specific issue or phenomenon may significantly impact one’s understanding
and acceptance (Clark et al., 2000). As such, physicians’ attitudes and support for MM
may be linked to their perceptions of the empirical evidence in support of this novel
treatment.
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CHAPTER 3: METHOD
Design and Design Justification
This study employed a correlational design using a self-administered, online
survey (i.e., PCOM REDCap) to collect quantitative and qualitative information from
licensed and actively practicing physicians in the United States (N = 24). The specific
variables studied were demographic information, level of support for medical marijuana
(MM), perceptions of the strength of supporting research on MM, and attitudes toward
MM. Twenty-three qualifying medical conditions were selected because they had
received approval by the Pennsylvania Department of Health. This design was selected
because it was a cost-effective way of gathering the desired information from a very
specific population during a pandemic.
Participants
This study involved 24 physician participants. Eligible participants included
physicians currently licensed in the United States (MD or DO) and who were currently
practicing within the medical field. Physicians who were no longer in practice or worked
solely in a teaching or research capacity were excluded. Potential participants were
screened prior to starting the demographic questionnaire that was provided at the
beginning of the survey.
Materials
The introduction to the survey link used to help recruit participants follows:
Introduction
Hello, my name is Philip Kaplan and I am a 5th year doctoral candidate for the
clinical Psy. D program at Philadelphia College of Osteopathic Medicine under the
supervision of Dr. David S. Festinger, my dissertation Chair. The goal of the study is to
examine the relationship between physicians’ knowledge, attitudes, and beliefs about
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medical marijuana as an effective form of treatment for various health conditions in the
state of PA. If you choose to participate, your responses, identity, and personal
information will remain completely confidential.
You may participate if you:
•

Are a licensed physician in the state of PA

•

Actively practicing within the medical field

If interested, please click on the link to the survey below. If you have any questions
please reach out to me at philipka@pcom.edu. Thank you for taking the time to read this!
Inclusion Criteria
To be included in the study, participants had to be licensed and actively practicing
physicians (MD or MO).
Exclusion Criteria
This study did not feature any exclusion criteria if the inclusion criteria were met.
Participants were informed of who was eligible to take part in the study before they
pressed the link to the survey. Additionally, the first few survey questions inquired about
the previously listed inclusion criteria to determine eligibility.
Recruitment
The survey link generated by REDCap was posted to the private PCOM Alumni
Facebook group page, and permission was obtained to post on other physician-focused
Facebook pages and listservs. The study recruited physician-level participants using
ResearchMatch.org.
Measures
Demographic Information
Demographic information was collected from answers to questions regarding
whether each participant was currently licensed as a physician in the United States, if
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they were currently practicing, years of medical experience, age, sex, gender,
race/ethnicity, years of practice, and medical specialty.
Support for Medical Marijuana Use
A binary (Yes/No) question was asked to determine whether participants would
support MM to treat the following 23 health conditions:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

•
•
•
•

Amyotrophic lateral sclerosis
Autism
Cancer
Crohn's disease
Dyskinetic disorders
Damage to the nervous tissue of the spinal cord with objective neurological
indication of intractable spasticity
Epilepsy
Glaucoma
HIV / AIDS
Huntington's disease
Inflammatory bowel disease
Intractable seizures
Multiple sclerosis
Neurodegenerative disorders
Neuropathies
Opioid use disorder
Parkinson's disease
Post-traumatic stress disorder
Severe chronic or intractable pain of neuropathic origin or severe chronic or
intractable pain in which conventional therapeutic intervention and opiate therapy
are contraindicated or ineffective
Sickle cell anemia
Terminal illness
Anxiety
Tourette’s syndrome

For each medical condition, potential participants were asked the following
question: “Would you support medical marijuana to treat this condition?” Responses to
this binary variable were condensed to serve as the dependent variable for the study as
follows: participants marked Y for “Yes” and N for “No” for each condition.
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Perception of Empirical Evidence
The perceived strength of the existing evidence-based research for the use of MM
was examined using a 5-point Likert-type scale. Specifically, the question asked,
“Overall, how strong is the empirical evidence in support of MM to treat the approved
conditions?” The Likert-type scale was as follows: 1- very weak, 2-weak, 3-mixed, 4strong, 5-very strong for each medical condition.
Provider Attitudes and Beliefs Regarding Medical Cannabis in General
The Provider Attitudes and Beliefs Regarding Medical Cannabis in General
survey is a measure composed of eight statements aimed at examining whether
physicians view marijuana as a legitimate, effective, and safe form of treatment. It is an
existing scale that had physicians rate the degree to which they either agreed or disagreed
with each statement by using a 5-point Likert scale with scores of 1 and 2 being strongly
disagree and somewhat disagree, respectively, a score of 3 being neither agree nor
disagree, and scores of 4 and 5 being somewhat agree and strongly agree, respectively.
For the purposes of this study, this scale was incorporated and used, but upon further
review, only the first question from this scale was used in order to be able to quantify and
generalize the results more accurately. The Likert Scale is a rating scale that is commonly
used in questionnaires and surveys as a means of collecting data.
Statistical Analysis Plan
Descriptive statistics were used to characterize the sample and examine the
distribution of the different variables.
Bivariate correlations were used to examine the relationship between
participants’ demographic characteristics, their support for recommending MM for
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various medical conditions, their perceptions of empirical evidence for MM, and their
attitudes toward MM. These analyses were conducted in order to identify any instances of
multicollinearity and to identify demographic variables that were significantly correlated
with the dependent variables, indicating they should be included in the regression models.
A linear regression was conducted to examine the degree to which perceptions of
empirical evidence for MM (Hypothesis 1), and attitudes toward MM (Hypothesis 2)
would predict likelihood of recommending MM for the various medical conditions.
Demographic variables that were found to be correlated with the dependent variables
were included in the regression model. In order to achieve this, a correlational matrix was
implemented.
To use linear regression, assumptions that must be met include (a) a linear
relationship between continuous predictors and the logit of the outcome variable, (b)
independence of observed data points, and (c) multicollinearity (Field, 2013). For
descriptive purposes, the proportion and number of physician participants who indicated
that MM should be used for each condition were also analyzed and reported. A power
analysis for a linear regression with three predictors was incorporated and estimated for a
moderate effect size. This study used an alpha of .05, which indicated that a sample of
approximately 107 would be required to achieve statistical power of .80.
Procedure
The student researcher went through the necessary procedural steps to gain IRB
approval for the study. Once this was achieved, the student researcher programmed his
dissertation survey into the REDCap program. The survey link generated by REDCap
was posted to the private PCOM Alumni Facebook group page, and permission was
obtained to post on other physician-focused Facebook pages and listservs. The study
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recruited physician-level participants using ResearchMatch.org. Participants were
informed of who was eligible to take part in the study (i.e., licensed physicians in the
United States who were currently practicing) before they pressed the link to the survey.
Additionally, the first few survey questions inquired about the previously listed inclusion
criteria to determine eligibility. Potential participants who did not meet criteria were
directed to a separate page that thanked them for their time and informed them that they
were not eligible to continue the survey. Potential participants who did meet criteria were
taken to the demographic section of the survey, which featured questions regarding years
of medical experience, age, sex, and gender. Once this information was completed,
participants then moved on to the second, third, and fourth sections of the survey. The
second and third sections of the survey used a Likert scale to measure participants’ levels
of support for the use of MM to treat each of the 23 health conditions and to measure the
amount of empirical evidence they believed existed to support marijuana’s efficacy as a
form of treatment for each health condition. The fourth section used an existing Likert
scale to measure participants’ attitudes toward recreational and medical use of cannabis.
Once the survey was completed, each participant was directed to a different page that
thanked them for their time, and the survey was then exported to SPSS for further
statistical analysis.
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CHAPTER 4: RESULTS
Participant Characteristics
The sample group (n = 24) consisted of 15 (62.5%) male and nine (37.5%) female
physician participants with a mean age of 45.7 years (SD = 13.45). A total of 31
participants responded to the survey; however, seven participants were dropped because
they did not complete the entire survey, including essential outcome variables related to
evidence and attitudes. Of the sample, 83.4% identified themselves as Caucasian, 4.2%
identified themselves as Black or African American, and 12.5% identified themselves as
Asian or Asian American. Of the sample, 8.3% identified their ethnicity as
Latinx/Hispanic, and 91.7% of the sample identified as non-Latinx/Hispanic. Of the total
sample of 24 physician participants, 17 (70.8%) reported that they did not have a license
to recommend medical marijuana (MM) as opposed to the 7 (29.2%) that reported they
did (see Table 1).
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Table 1
Demographics
Variable

M (SD)/N (%)

Age

45.67 (13.45)

Biological sex
Male

15 (62.5)

Female

9 (37.5)

Race
Caucasian

20 (83.4)

Black or African American

1 (4.)

Asian or Asian American

3 (12.5)

Ethnicity
Latinx/Hispanic

2 (8.3)

Non-Latinx/Hispanic

22 (91.7)

Certified to recommend medical marijuana
Yes

7 (29.2%)

No

17 (70.8%)

In regard to medical specialty, the vast majority of the participants reported
specializing in either neurology (33.3%) or psychiatry (25%), followed by internal
medicine (16.7%), family medicine (8.3%), other (8.3%), general internal (4.2%), and
anesthesiology (4.2%; see Table 2). From the total sample group (n = 24), the mean score
for total years in practice was 15.65 (SD = 15.34; see Table 2).
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Table 2
Medical Specialty
Medical Specialty

N (%)/ M (SD)

Family medicine

2 (8.3%)

General internal

1 (4.2%)

Neurology

8 (33.3%)

Anesthesiology

1 (4.2%)

Internal medicine

4 (16.7%)

Psychiatry

6 (25%)

Other

2 (8.3%)

Years of practice

15.65 (15.34)

The sample group provided some geographical diversity, notably from 12 different
states in total. When asked the state each physician practiced in, the vast majority
reported that they were practicing in New York (33.3%), Pennsylvania (16.7%), or New
Jersey (12.5%). The rest of the sample practiced in nine other states (Arizona, Colorado,
Illinois, Louisiana, North Dakota, Ohio, South Carolina, Texas, and Virginia), each of
which consisted of 4.2% of the sample (see Table 3).
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Table 3
State Practicing
State practicing

N (%)

AZ

1 (4.2%)

CO

1 (4.2%)

IL

1 (4.2%)

LA

1 (4.2%)

NJ

3 (12.5%)

NY

8 (33.3%)

ND

1 (4.2%)

OH

1 (4.2%)

PA

4 (16.7%)

SC

1 (4.2%)

TX

1 (4.2%)

VA

1 (4.2%)

This study aimed to examine whether physicians’ level of support for MM would
be significantly and positively associated with their perceptions of the strength of its
empirical evidence and their attitudes toward MM. This study also aimed to examine
whether physicians’ perceptions of evidence would be significantly and positively
correlated with their attitudes. SPSS 24.0 was used to analyze the variables of interest.
Bivariate correlations were conducted to examine the associations between the
dependent variable (i.e., physician’s level of support for MM), the hypothesized
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independent variables (i.e., perception of evidence, attitudes toward MM), and
demographic variables (i.e., age, biological sex, race, ethnicity, years of practice, and
certified to recommend; see Table 4). Significant inverse associations were identified
between the dependent variable (i.e., support for MM) and the demographic variables:
age (R = -.43, p = .05) and years of practice (R = .-48, p = .05). Because age and years of
practice were so highly correlated (R = .96, p = .01), multicollinearity was indicated. As a
result, only years of practice was included in the linear regression model along with the
hypothesized independent variables (see Table 4).
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Table 4
Correlational Matrix of Demographics, Independent Variables, and Dependent Variable
Variable

Support Perceived Attitude
for
evid MM MM
MM

Age

Gender

Race

Years
MM
Practicing certified

Support for
MM

1.00

Perceived
evid for MM

.53**

1.00

Attitudes
toward MM

.79**

.49*

1.00

Age

-.43*

-.06

-.32

1.00

Gender

-.02

-.06

-.15

-.01

1.00

Race

-.13

-.16

-.14

-.28

-.12

1.00

Years
practicing

-.48*

-.15

-.44*

.96**

-08

-.28

1.00

MM certified

.24

.41

.35

.14

.07

-.31

.18

Note. ** p < .01
*p < .05

Hypothesis 1
It was hypothesized that physicians’ level of support for MM will be significantly
and positively associated with their perceptions of the strength of its empirical
evidence. As discussed earlier, years of practice was found to be significantly correlated
with level of support and, therefore, was entered into the regression model. The overall

1.00
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regression model was found to be significant, controlling for years of practice and
including attitudes, and perceived evidence was found to be significant, F(3, 21) = 9.63, p
= .001. While the overall model was significant, the hypothesized independent variable
(i.e., perceived evidence) was not (p = .21). The overall model explained approximately
62% of variance (r squared = .62), (see Tables 5, 6, and 7).

Table 5
Model Summary
Model

R

R Square

Adjusted R
Std. Error of
Square
the Estimate
a
1
.785
.616
.552
4.53990
a. Predictors: (Constant), Medical cannabis is a legitimate medical therapy. How long
have you been a practicing physician (in years)? Mean evidence rating.

Table 6
Anovaa
Model

Sum of

df

Mean square F

Sig
.001b

squares
Regression

595.372

3

198.457

Residual

370.992

18

20.611

Total

966.364

21

9.629

a. Dependent Variable: Number of conditions supported.
b. Predictors: (Constant), Medical cannabis is a legitimate medical therapy. How long
have you been a practicing physician (in years)? Mean evidence rating.
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Table 7
Coefficientsa
Model

Unstandardized Unstandardized Standardized
coefficients B

coefficients

Coefficients

Std. Error

Beta

t

Sig.

-.618

.544

(Constant)

-2.889

4.670

Practicing

-.080

.070

-.177

-1.136

.271

1.734

1.325

.218

1.309

.207

3.796

1.155

.577

3.287

.004

physician
(in years)?
Mean evid
rating.
MM is legit
medical
therapy.
a. Dependent Variable: Number of conditions supported.

Hypothesis 2
It was hypothesized that physicians’ level of support for MM will be significantly
and positively associated with their attitudes toward marijuana (medical or not). As
previously discussed under Hypothesis 1, attitudes toward MM was included in the
regression model along with years of practice and perceived evidence. The overall model
was significant and accounted for 62% of the variance in level of support. Findings
supported the hypothesis, indicating that attitudes were a significant predictor of level of
support (p = .004).
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Hypothesis 3
It was hypothesized that physicians’ perceptions of evidence will be significantly
and positively correlated with their attitudes toward MM. Results of the linear regression
were statistically significant, F(2, 21) = 4.25, p = .03. The model explained
approximately 31% of the variance (r squared = .309). The model coefficients indicated
that perceived evidence was as significant predictor of level of physician attitudes (B =
.53, p = .036), and years of practice fell below the level of statistical significance (B = .02, p = .154). See tables 8, 9, and 10.

Table 8
Model Summary
Model

R

R square

Adjusted R
Std. error of the
square
estimate
a
1
.556
.309
.236
.902
a. Predictors: (Constant), Mean evidence rating, How long have you been a practicing
physician (in years)?
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Table 9
Anovaa
Model

Sum of

df

squares

Mean

F

Sig.

4.246

.030b

square

Regression

6.908

2

3.454

Residual

15.455

19

.813

Total

22.364

21

a. Dependent Variable: Medical cannabis is a legitimate medical therapy.
b. Predictors: (Constant), Mean evidence rating, How long have you been a practicing
physician (in years)?

Table 10
Coefficientsa
Model

Unstandardized Unstandardized Standardized
Coefficients B

Coefficients

coefficients

Std. error

beta

t

Sig.

3.672

.002

(Constant)

2.605

.709

Practicing

-.020

.013

-.287

-1.486

.154

.527

.234

.435

2.256

.036

physician
(in years)?
Mean evid
rating
a. Dependent Variable: Medical cannabis is a legitimate medical therapy.
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CHAPTER 5: DISCUSSION
This study examined three hypotheses. The first hypothesis was that physicians’
level of support for medical marijuana (MM) would be significantly and positively
associated with their perceptions of the strength of its empirical evidence. Although
Hypothesis 1 was not supported, the overall linear regression was significant when
combined with years of practice and physicians’ attitudes, suggesting that with a greater
sample size, the results may have differed and that an association may exist between
physicians’ perceptions of evidence, physicians’ total years of experience, and
perceptions of evidence. This study’s second hypothesis was that physicians’ level of
support for MM would be significantly and positively associated with their attitudes
toward marijuana (medical or not). The second hypothesis was supported, indicating that
physicians who have a more positive interpretation of MM as an effective form of
treatment would be more likely to recommend it and vice versa. This study’s third and
final hypothesis was that physicians’ perceptions of evidence would be significantly and
positively correlated with their attitudes toward MM. This hypothesis was supported,
indicating that if physicians believe that they possess enough data and empirical support,
they are more likely to develop a more concrete perspective on whether MM is effective
as treatment.
The results from Hypothesis 1 do not seem to be supported by the limited
literature that was found regarding this topic. According to a study conducted by Kondrad
and Reid (2013), the vast majority of the sample of 486 physicians reported that their
primary source of information on MM came from medical literature and personal
experiences with patients, which were also the two highest rated factors that helped
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determine whether they would recommend or not recommend MM to patients (decision
to recommend = 331, decision not to recommend = 152). The results from this study
contribute an alternative perspective within the literature on the associations between
physicians’ levels of support for MM and their perceptions of evidence regarding its
efficacy. This also may present an opportunity for future studies to replicate this
dimension of research to examine the consistency of the results between these two
factors.
The results from Hypothesis 2 seem to be supported by the limited literature that
was found regarding this topic. A study conducted by Lombardi et al. (2020) found that
from a sample of 314 physicians, a statistically significant relationship existed between
physicians’ likelihood to recommend MM and their opinions that it should be legal and
possessed medicinal uses. Physicians were twice as likely to recommend MM if they
believed it should be legalized and believed that it was associated with positive health
benefits. A study conducted by Charuvastra et al. (2005) found significant associations
between physicians’ attitudes and their level of support to recommend MM. The results
from this study help reinforce and support existing literature that was found regarding
this topic.
The results from Hypothesis 3 are consistent with the limited literature that exists
on the topic. According to Lombardi et al. (2020), physicians who reported concern
regarding lack of evidence of MM’s efficacy as a form of treatment and who were
worried about it psychoactive effects presented an inverse relationship to their likelihood
to recommend MM to patients. In addition, a study conducted by Kansagara et al. (2020)
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found that from a sample of 249 physicians, 90% reported that peer-reviewed literature
influenced their attitudes toward MM.
This study did note, however, some physicians’ gaps in knowledge, for
example,27% reported not possessing the awareness of current research surrounding
potential benefits/harms of cannabis use, 58% were unfamiliar with the term “dabbing,”
and 40% did not believe cannabis could be addictive. The results from this study help
reinforce and support existing literature found regarding this topic.
According to cognitive behavioral theory, the way in which individuals perceive a
situation and/or topic tends to influence their reactions and behaviors rather than the
situation itself. In relation to physicians and their perceptions of MM, some physicians
may have biased and/or inaccurate conceptualizations of MM. Some physicians, for
instance, may believe that MM exclusively possesses negative side effects, despite some
evidence that indicates that MM may help individuals increase their appetites and
improve sleep. Other physicians may exclusively focus on the benefits of MM while
discounting or lacking knowledge of some of the potential drawbacks of MM. Cognitivebehavioral theory training opportunities may help medical students and future physicians
develop a more concrete awareness of the pros and cons of MM, especially if it were to
become part of their curriculum.
Some additional findings occurred after the bivariate correlations were conducted.
Significant inverse associations were identified between independent variable (i.e.,
physician attitude toward MM) and the demographic variable, years of practice. This
finding suggests that physicians who were more experienced possessed less supportive
attitudes toward MM as an efficacious form of treatment. This was further supported by
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the finding that the demographic feature of age possessed significant inverse associations
with the dependent variable of physicians’ level of support for MM, further reinforcing
the idea that physicians who were older and more experienced possessed less supportive
attitudes toward MM.
Implications
The results of this study point to a few primary implications. One of these
implications is that physicians’ perceptions of evidence impacted physicians’ attitudes,
yet did not impact physicians’ levels of support for MM. Additionally, both physicians’
age and years of practice were significantly correlated to one another and had an inverse
correlation to physicians’ attitudes. Another implication, also strongly supported by the
literature, was that most physicians and healthcare providers agreed that the medical field
could benefit from additional research on MM and that providing additional education
and training opportunities on the empirical support for MM for various health conditions
may be important. Findings from this study have provided an improved, but limited
understanding of the factors that impact physicians’ varying attitudes and support for
MM. This may help to inform continued policy efforts related to MM and strategies to
address physicians’ knowledge and perceptions regarding its use. Findings have shed
some light on physicians’ likelihood of recommending MM for the different approved
conditions and on their confidence in the strength of supporting research for the efficacy
of MM for each condition.
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Strengths
One of the strengths of this study was its focus on examining variable associations
that have limited previous research and its moderate geographic diversity (i.e.,
participants from 12 different states). Additionally, although the small sample size of this
study should be considered a limitation, one should note that despite this limitation, two
of the three hypotheses were supported, an outcome quite uncommon among research
studies with smaller sample sizes. Another strength of the study was its use of a selfreport survey format, which was very cost effective, allowed results to be easily obtained,
and could be completed more quickly compared to other approaches. Additionally, the
two Likert scales implemented in measuring physicians’ levels of support and
perceptions of evidence for MM helped draw conclusions more clearly, based on whether
variables met statistical significance or not.
Limitations
Some of the limitations in this study included a small sample size (nine of 12)
states had only one participant), making generalizability of these results difficult. In
addition to the small sample size, participants represented a wide variety of medical
specialties, further diluting the sample. Another limitation of the study was that it used a
self-report measure. Although such an approach was a quick and convenient way of
gathering data, the potential drawback of such an approach was that participants may
have provided responses that were socially acceptable rather than based on their genuine
beliefs. Additionally, several participants did not complete the survey, another common
drawback of implementing a self-report measure.
Another limitation of the study included the measurement scales themselves. The
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Support for Medical Marijuana Use scale consisted of binary “Yes/No” response options,
which severely limited participants’ abilities to elaborate on their responses. Furthermore,
for the Perception of Empirical Evidence scale, which consisted of a 5-point-Likert scale,
provided no option for participants who were uncertain or did not know the amount of
evidence that existed in support of MM’s effectiveness to treat each medical condition.
This may have been a contributing factor as to why some participants left some questions
blank in this section and/or stopped doing the survey altogether. The Attitudes (Provider
Attitudes and Beliefs Regarding Medical Cannabis in General) scale consisted of a oneitem, 5-point Likert scale, which limited participants’ abilities to elaborate on their
responses and/or to express their uncertainty, as this once again was not an option
provided.
Future Directions
Based on the findings from this study, several future directions may be worth
exploring. Future directions could include replicating this study with a larger sample,
possibly providing more insight as to physicians’ similarities and differences from one
another based on medical specialty and region of practice. Another possible direction for
future research is to continue to examine the sources of information (e.g., media,
literature, clients, other physicians’ views) physicians rely on most frequently to help
them frame their clinical impressions regarding MM as an efficacious form of treatment.
Future research may also examine how age and years of practice may be associated with
attitudes toward MM, and whether this can be addressed with specialized training. Other
future directions may include examining the similarities/differences among physicians
who are licensed to recommend MM versus those who are not licensed and the
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reasons/arguments they developed to support their clinical perspectives. Such research
may also help re-contextualize state laws and any pending legislations regarding
MM throughout the country and even in different regions of the world.
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APPENDIX
SURVEY
Section 1:
Demographic Information
1. Age: ___
2. Sex: ____
3. Ethnicity: ________
4. Are you a currently licensed physician in the state of Pennsylvania? (Y/N).
5. Are you currently practicing? (Y/N).
6. How long have you been a practicing physician? ______
7. Are you certified to recommend medical marijuana? (Y/N).
8. What is your scope of practice?
9. What is your medical specialty? ______
Section 2:
Support for Use of Medical Marijuana
Please mark Y for “yes” or N for “no” regarding whether you would support medical
marijuana as a form of treatment for each medical condition.
1. Amyotrophic Lateral Sclerosis
Would you support medical marijuana to treat this condition? (Y/N).
2. Autism
Would you support medical marijuana to treat this condition? (Y/N).
3. Cancer
Would you support medical marijuana to treat this condition? (Y/N).
4. Crohn's Disease
Would you support medical marijuana to treat this condition? (Y/N).
5. Dyskinetic Disorders
Would you support medical marijuana to treat this condition? (Y/N).
6. Damage to the nervous tissue of the spinal cord with objective neurological
indication of intractable spasticity
Would you support medical marijuana to treat this condition? (Y/N).
7. Epilepsy
Would you support medical marijuana to treat this condition? (Y/N).
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8. Glaucoma
Would you support medical marijuana to treat this condition? (Y/N).
9. HIV/AIDS
Would you support medical marijuana to treat this condition? (Y/N).
10. Huntington's Disease
Would you support medical marijuana to treat this condition? (Y/N).
11. Inflammatory Bowel Disease
Would you support medical marijuana to treat this condition? (Y/N).
12. Intractable Seizures
Would you support medical marijuana to treat this condition? (Y/N).
13. Multiple Sclerosis
Would you support medical marijuana to treat this condition? (Y/N).
14. Neurodegenerative Disorders
Would you support medical marijuana to treat this condition? (Y/N).
15. Neuropathies
Would you support medical marijuana to treat this condition? (Y/N).
16. Opioid Use Disorder
Would you support medical marijuana to treat this condition? (Y/N).
17. Parkinson's Disease
Would you support medical marijuana to treat this condition? (Y/N).
18. Post-traumatic Stress Disorder
Would you support medical marijuana to treat this condition? (Y/N).
19. Severe chronic or intractable pain of neuropathic origin or severe chronic or
intractable pain in which conventional therapeutic intervention and opiate therapy
is contraindicated or ineffective
Would you support medical marijuana to treat this condition? (Y/N).
20. Sickle Cell Anemia
Would you support medical marijuana to treat this condition? (Y/N).
21. Terminal Illness
Would you support medical marijuana to treat this condition? (Y/N).
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22. Anxiety
Would you support medical marijuana to treat this condition? (Y/N).
23. Tourette’s Syndrome
Would you support medical marijuana to treat this condition? (Y/N).
Section 3:
Perception of Empirical Evidence:
Overall, how strong is the empirical evidence in support of medical marijuana to treat the
approved conditions?
1. Amyotrophic Lateral Sclerosis
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

2. Autism
1-Very weak

2-Weak

3-Mixed

4-Strong

5-Very Strong

3. Cancer
1-Very weak

2-Weak

3-Mixed

4-Strong

5-Very Strong

4. Crohn's Disease
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

5. Dyskinetic Disorders
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

6. Damage to the nervous tissue of the spinal cord with objective neurological
indication of intractable spasticity
1-Very weak
2-Weak
3-Mixed
4-Strong
5-Very Strong
7. Epilepsy
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

8. Glaucoma
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

9. HIV/AIDS
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

10. Huntington's Disease
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

4-Strong

5-Very Strong

11. Inflammatory Bowel Disease
1-Very weak

2-Weak

3-Mixed
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12. Intractable Seizures
1-Very weak

2-Weak

3-Mixed

4-Strong

5-Very Strong

13. Multiple Sclerosis
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

14. Neurodegenerative Disorders
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

15. Neuropathies
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

16. Opioid Use Disorder
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

17. Parkinson's Disease
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

18. Post-traumatic Stress Disorder
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

19. Severe chronic or intractable pain of neuropathic origin or severe chronic or
intractable pain in which conventional therapeutic intervention and opiate therapy
is contraindicated or ineffective
1-Very weak
2-Weak
3-Mixed
4-Strong
5-Very Strong
20. Sickle Cell Anemia
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

21. Terminal Illness
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

22. Anxiety
1-Very weak
2-Weak

3-Mixed

4-Strong

5-Very Strong

23. Tourette’s Syndrome
1-Very weak
2-Weak
3-Mixed

4-Strong

5-Very Strong

Section 4:
Attitudes Toward Medical Marijuana
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Provider Attitudes and Beliefs Regarding Medical Cannabis in General
1. Medical cannabis is a legitimate medical therapy.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
2. Medical providers should be offering medical cannabis for managing medical
conditions.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
3. Medical cannabis has significant interactions with medical therapies.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
4. Medical cannabis can effectively treat symptoms associated with medical
conditions.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
5. The process to certify patients in the medical cannabis program prevents me from
enrolling patients.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
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6. I am aware that patients use cannabis illegally to treat symptoms or medical
conditions.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
7. Medical cannabis through the United States is safer than cannabis that patients use
illegally.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree
8. Medical cannabis through the United States is more effective than cannabis that
patients use illegally.
1-Strongly disagree
2-Somewhat Disagree
3-Neither Agree nor Disagree
4-Somewhat Agree
5-Strongly Agree

